XERS vs. CTMX, XBIT, ENTA, RAPT, NKTR, ELYM, INZY, XOMA, CTNM, and VSTM
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include CytomX Therapeutics (CTMX), XBiotech (XBIT), Enanta Pharmaceuticals (ENTA), RAPT Therapeutics (RAPT), Nektar Therapeutics (NKTR), Eliem Therapeutics (ELYM), Inozyme Pharma (INZY), XOMA (XOMA), Contineum Therapeutics (CTNM), and Verastem (VSTM). These companies are all part of the "pharmaceutical preparations" industry.
CytomX Therapeutics (NASDAQ:CTMX) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.
CytomX Therapeutics has higher earnings, but lower revenue than Xeris Biopharma. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
CytomX Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500.
67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 7.0% of CytomX Therapeutics shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
CytomX Therapeutics presently has a consensus price target of $4.75, suggesting a potential upside of 13.37%. Xeris Biopharma has a consensus price target of $4.88, suggesting a potential upside of 163.51%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Xeris Biopharma is more favorable than CytomX Therapeutics.
In the previous week, CytomX Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 11 mentions for CytomX Therapeutics and 8 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.40 beat CytomX Therapeutics' score of 0.12 indicating that CytomX Therapeutics is being referred to more favorably in the media.
CytomX Therapeutics has a net margin of -0.56% compared to CytomX Therapeutics' net margin of -37.98%. Xeris Biopharma's return on equity of 0.00% beat CytomX Therapeutics' return on equity.
CytomX Therapeutics received 230 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.50% of users gave Xeris Biopharma an outperform vote while only 66.13% of users gave CytomX Therapeutics an outperform vote.
Summary
CytomX Therapeutics beats Xeris Biopharma on 11 of the 18 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
